Replies to post #525127 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I completely disagree that the 35 patient group encompassed any DCVax-l recipients.

Instead, JTM 2018

Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L.

Note: 331 - 35 = 296

296/331= 89.4%

Or “nearly 90%”

[Doc logic]

GermanCol,

Keep up the good work. Really appreciated and will help new folks to the board catch up on some of what we are (almost; ) all excited about. Best wishes.